Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Inozyme Pharma secures $49m funding for rare disease therapies Inozyme Pharma, which is developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, has raised a $49m Series A financing.
Drug Research > Drug Discovery & Development > News
Purdue Pharma to invest in oncology research and development Purdue Pharma says that it has finalized major oncology related investments as part of its move to diversify its scientific research into areas of high unmet medical need.
Drug Research > Drug Discovery & Development > News Bayer and Loxo Oncology to develop and commercialize two cancer therapies Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Purdue Pharma to invest in oncology research and development
Purdue Pharma says that it has finalized major oncology related investments as part of its move to diversify its scientific research into areas of high unmet medical need.
Drug Research > Drug Discovery & Development > News
Bayer and Loxo Oncology to develop and commercialize two cancer therapies
Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.
Drug Research > Drug Discovery & Development > News
EMA grants PRIME designation for Mereo’s BPS-804 to treat osteogenesis imperfecta
Mereo BioPharma Group’s BPS-804 has been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of osteogenesis imperfecta (OI), or "brittle bone disease."
Drug Research > Drug Discovery & Development > News
Research indicates potential treatment for autism and intellectual disability
A University of Nebraska Medical Center researcher and his team at the Munroe-Meyer Institute (MMI) made a breakthrough in finding the mechanism and a possible therapeutic fix for autism and intellectual disability
Drug Research > Drug Discovery & Development > News
Sanofi to develop Principia’s MS drug candidate in $805m deal
By PBR Staff Writer
Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.
Drug Research > Drug Discovery & Development > News
Boehringer, MiNA Therapeutics partner to develop novel treatments for fibrotic liver diseases
By PBR Staff Writer
Boehringer Ingelheim has entered into collaboration and licensing agreement with MiNA Therapeutics for the development of novel treatments to treat fibrotic liver diseases.
Drug Research > Drug Discovery & Development > News
Cerenis Therapeutics acquires Lypro Biosciences
Cerenis Therapeutics has acquired Lypro Biosciences to expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery.
Drug Research > Drug Discovery & Development > News
New international consortium formed to speed up drug discovery in kidney diseases
By PBR Staff Writer
A new international consortium, including academic institutions such as the Universities of Bristol and Cambridge and drugmaker Evotec, has been established to enhance the discovery of drugs to treat kidney diseases.
Drug Research > Drug Discovery & Development > News
Spark Therapeutics, Pfizer amend license deal for investigational SPK-9001 in hemophilia B
Spark Therapeutics and Pfizer have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B.
Drug Research > Drug Discovery & Development > News
Xenetic signs sublicense deal related to PolyXen technology with Baxalta
Xenetic Biosciences has entered into a Right to Sublicense Agreement with Baxalta, Baxalta, and Baxalta (collectively, with their affiliates, “Baxalta”), wholly-owned subsidiaries of Shire.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests